Publications
2015-2019
2019
RNA Sequencing of the NCI-60: Integration into CellMiner and CellMiner CDB
2019 May 21
A novel assay to screen siRNA libraries identifies protein kinases required for chromosome transmission
2019 August 21
Tyrosyl-DNA Phosphodiesterase 1 and Topoisomerase I Activities as Predictive Indicators for Glioblastoma Susceptibility to Genotoxic Agents
2019 September 23
Quantitative Proteome Landscape of the NCI-60 Cancer Cell Lines
2019 November 22
2018
Rapid proteotyping reveals cancer biology and drug response determinants in the NCI-60 cells
2018 Feb 01
CellMiner and CellMiner Cross-Database (CDB): resources for the exploration of pharmacogenomics using cancerous cell-lines
2018 March 05
ONC201 kills breast cancer cells in vitro by targeting mitochondria
2018 April 06
Macrophilones from the Marine Hydroid Macrorhynchia philippina Can Inhibit ERK Cascade Signaling
2018 July 06
CellMinerCDB for Integrative Cross-Database Genomics and Pharmacogenomics Analyses of Cancer Cell Lines
2018 Dec 21
2017
Temozolomide in the Era of Precision Medicine.
Cancer Res. 2017 Feb 15. [Epub ahead of print].
Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay.
Plos One. 2017 Feb 3.
The NCI-60 Methylome and its Integration into CellMiner.
Cancer Res. 2017 Feb 1. pii: [Epub ahead of print].
Cytidine deaminase deficiency reveals new therapeutic opportunities against cancer.
Clin Cancer Res. 2017 Apr 15. pii: clincanres.0626.2017. [Epub ahead of print].
2016
DNA-Targeted Precision Medicine; Have We Been Caught Sleeping?
Trends in Cancer. 2016 Dec 27. [Epub ahead of print].
A replicator-specific binding protein essential for site-specific initiation of DNA replication in mammalian cells.
Nat Commun. 2016 Jun 8;7:11748. doi: 10.1038/ncomms11748.
rcellminer: exploring molecular profiles and drug response of the NCI-60 cell lines in R.
Bioinformatics. 2016 Apr 15;32(8):1272-4. doi: 10.1093/bioinformatics/btv701. Epub 2015 Dec 3.
Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs.
Oncotarget. 2016 Jan 19;7(3):3084-97. doi: 10.18632/oncotarget.6413.
2015
Current dichotomy between traditional molecular biological and omic research in cancer biology and pharmacology.
World J Clin Oncol. 2015 Dec 10;6(6):184-8. doi: 10.5306/wjco.v6.i6.184.
Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60.
Clin Cancer Res. 2015 Jun 5. pii: clincanres.0335.2015. [Epub ahead of print].
Bisphosphonates as new anticancer agents?
Bull Cancer. 2015 Apr;102(4):297-9.
The 15kDa selenoprotein and thioredoxin reductase 1 promote colon cancer by different pathways.
PLoS One. 2015 Apr 17;10(4):e0124487.
Alterations of DNA repair genes in the NCI-60 cell lines and their predictive value for anticancer drug activity.
DNA Repair. 2015 Feb 11. pii: S1568-7864(15)00023-3.
Using drug response data to identify molecular effectors, and molecular "omic" data to identify candidate drugs in cancer.
Hum Genet. 2015 Jan;134(1):3-11. doi: 10.1007/s00439-014-1482-9. Epub 2014 Sep 12.